Published in Cancer J on September 11, 2003
Update on options for treatment of metastatic castration-resistant prostate cancer. Onco Targets Ther (2010) 1.00
Assessing outcomes in prostate cancer clinical trials: a twenty-first century tower of Babel. Cancer (2008) 0.88
Pigment epithelium-derived factor expression prolongs survival and enhances the cytotoxicity of low-dose chemotherapy in castration-refractory prostate cancer. Cell Death Dis (2014) 0.82
Chemotherapy for Late-Stage Cancer Patients: Meta-Analysis of Complete Response Rates. F1000Res (2015) 0.77
Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer. Oncologist (2002) 1.05
Does race affect outcomes in triple negative breast cancer? Breast Cancer (Auckl) (2010) 0.84
Docetaxel and carboplatin as first-line therapy in advanced non-small cell lung carcinoma: a phase II study. Anticancer Res (2004) 0.76
A retrospective study evaluating a fixed low dose capecitabine monotherapy in women with HER-2 negative metastatic breast cancer. Breast Cancer Res Treat (2014) 0.76